Independent Pharmacy Taxes: The Inventory, the PBM Clawbacks, the DIR Fees, and LIFO for a Drug Shelf That Only Gets More Expensive

An independent pharmacy is an inventory business whose customers are insurance plans, and the return follows the shelf. The inventory — the return's center: prescription drugs (brand and generic), the over-the-counter products, and the front-store merchandise are inventory — cost of goods sold is opening inventory plus purchases (from the primary wholesaler, the secondary wholesalers, and the direct-from-manufacturer purchases) less closing inventory, with the year-end physical count (the pharmacy's inventory service counts the shelf at year-end — the standard practice, and the only reliable figure for a stock of thousands of items) setting the closing value; the wholesaler's rebates (the generic rebate programs, the prompt-pay discounts, the volume incentives through the pharmacy services administrative organization — reductions in the cost of the drugs purchased, recognized as they're earned under the program's terms) reduce cost of goods sold; the cost of drugs dispensed runs 75 to 85 percent of prescription revenue, so the gross margin — and the tax — moves with a few points of reimbursement or acquisition cost. LIFO — the pharmacy's election: drug prices rise nearly every year (brand drugs' list prices especially — generics can deflate, so LIFO's benefit depends on the pool's index actually rising), so a pharmacy using first-in, first-out inventory reports its cost of goods sold at the older, lower prices and its closing inventory at the newer, higher ones — taxable profit includes the inflation in its shelf; the last-in, first-out method (LIFO) reverses it — cost of goods sold at the most recent prices, the closing inventory carried at the older layers — deferring the tax on the inflation for as long as the inventory isn't liquidated; independent pharmacies adopt LIFO (usually the dollar-value method with an index — the Inventory Price Index Computation (IPIC) method, which uses the Bureau of Labor Statistics' price indexes and is open to any dollar-value LIFO taxpayer, or the simplified dollar-value method of section 474 for businesses averaging US$5 million or less of gross receipts, keeps the computation manageable) by filing Form 970 with the return for the year of adoption; the LIFO conformity rule requires the pharmacy's financial statements to use LIFO too (a lender's covenants may need attention), and a later liquidation (the pharmacy reduces its inventory — or sells) brings the deferred inflation back into income — the LIFO reserve is a real deferred tax a buyer's diligence prices. Revenue and the PBMs: most prescriptions are paid by a third party — commercial plans, Medicare Part D plans, and Medicaid managed care — through pharmacy benefit managers that adjudicate the claim at the counter (the pharmacy receives the copay from the patient and the plan's reimbursement from the PBM weeks later through its payment cycle); the reimbursement formula (the maximum allowable cost for generics, a discount off the list price for brands, plus a dispensing fee) is set by the PBM's contract, often below the pharmacy's acquisition cost for some drugs; and the PBMs then take money back after the claim is paid — the direct and indirect remuneration (DIR) fees and the performance-based clawbacks that for years were assessed months after the claim (in Medicare Part D, a CMS rule effective January 1, 2024 requires all pharmacy price concessions to be reflected in the negotiated price at the point of sale — the Part D fees now come off the claim at the counter rather than months later; commercial plans' post-adjudication fees continue in many contracts), the audit recoupments (a PBM audit finding a documentation error recoups the entire claim), and the network fees; under the cash method, the reimbursement is income when received and a clawback is a reduction of income (or a deduction) when it is withheld from a later payment or paid; a pharmacy that projects on the adjudicated amounts without the expected fees over-projects its income; the reconciliation software (matching the PBM's remittances to the claims adjudicated) is the pharmacy's revenue control. The front store: over-the-counter medications, health and beauty products, greeting cards, the gift items, the durable medical equipment (a separate billing regime with Medicare — the DMEPOS accreditation and competitive bidding) — inventory with its own margin, and sales tax: prescription drugs are exempt in nearly every state; over-the-counter drugs are taxable in many states and exempt in others; the front-store merchandise is taxable; the durable medical equipment on prescription is often exempt (the rules vary by state); the point-of-sale system taxes by item category. Compliance — deductible because mandatory: the state board of pharmacy's permit for the pharmacy and the licenses for each pharmacist and technician, the DEA registration and the controlled-substance recordkeeping (the biennial inventory, the ordering forms, the theft and loss reporting — the dental deductions guide's DEA point, at a pharmacy's scale), the state prescription drug monitoring program's reporting, the Drug Supply Chain Security Act's product tracing, the HIPAA program (the HHS rules), the Medicare and Medicaid enrollments, the PBM network credentialing, the accreditation some networks require, and the continuing education — all deductible. Staff: pharmacists (the largest non-inventory cost — the pharmacist-in-charge and the staff pharmacists at the market wage for the profession), technicians, and front-store clerks on payroll; the owner-pharmacist's salary (the pharmacy entity point — below). The equipment and the technology: the pharmacy management system (the dispensing software — a large subscription), the automation (a counting machine, a robot, the adherence packaging machine — section 179 or bonus), the refrigeration for vaccines and biologics, the point-of-sale system, the delivery vehicle, and the build-out of the pharmacy area (qualified improvement property in a leased space — the leasehold improvements guide). The clinical services: immunizations, medication therapy management, the point-of-care tests, the compounding — revenue by service with the costs of the supplies and the pharmacist's time; the vaccine inventory's cost as cost of goods sold. Insurance: professional liability (the pharmacist's error — a dispensing error's claim), general liability, the property and the inventory (a pharmacy's inventory is valuable and a target), the crime and theft coverage, workers' compensation, and cyber. Entity and the specified service question: pharmacy is in the health field — the regulations name pharmacists — so the QBI deduction phases out above the taxable-income range; the front-store retail line is part of the same trade or business unless genuinely separated (the de minimis rule — a pharmacy's retail receipts usually don't make it non-SSTB, and separating a front store into its own business with its own books and staff is uncommon but possible for a large one — the veterinary entity guide's boarding example). The bookkeeping: purchases by wholesaler with rebates; the year-end inventory service count; LIFO computations and the reserve; claims adjudicated by PBM with remittances reconciled; DIR and clawbacks by PBM and period; audit recoupments; front-store sales and sales tax by category; payroll; compliance; equipment. The errors: inventory estimated rather than counted; LIFO never considered for a pharmacy whose inventory inflates every year; clawbacks unrecorded until the PBM's year-end reconciliation; the rebates ignored; over-the-counter drugs taxed as prescriptions (or the reverse); and the DEA biennial inventory skipped.

Key takeaways

• Cost of drugs dispensed is 75–85 percent of prescription revenue — computed from purchases, wholesaler rebates, and a year-end physical count by an inventory service; a few points of reimbursement move the whole return.
• LIFO defers the tax on a shelf whose prices rise every year — adopted on Form 970 (often with a simplified dollar-value index method), subject to the conformity rule, and reversed on liquidation; the LIFO reserve is a deferred tax a buyer prices.
• PBMs pay after adjudication and take money back later — DIR fees, performance clawbacks, network fees, and audit recoupments reduce income when withheld or paid; reconcile remittances to claims.
• Prescriptions are exempt from sales tax nearly everywhere; over-the-counter drugs and front-store merchandise usually aren't — tax by item category.
• The DEA, the board of pharmacy, the monitoring program, product tracing, HIPAA, and network credentialing are mandatory and deductible.
• Pharmacy is a specified service trade — the QBI deduction phases out above the range; the front store rarely changes that.

The independent pharmacy's deduction file

Purchases by wholesaler; rebates by program. Year-end inventory service count. LIFO: Form 970; index method; reserve; conformity. Claims by PBM; remittance reconciliation; DIR fees and clawbacks by PBM and period; audit recoupments. Front store: inventory; sales tax by category. Clinical services revenue. Payroll: pharmacists, technicians, clerks. Compliance: board permits and licenses, DEA and biennial inventory, PDMP, DSCSA, HIPAA, enrollments, credentialing, CE. Equipment: management system, automation, refrigeration, build-out (QIP). Insurance (professional, GL, property and inventory, crime, workers' comp, cyber). The count and the PBM reconciliation are the return.

Worked example

An independent pharmacy fills 62,000 prescriptions and grosses US$4.8 million: US$4.3 million of prescription revenue (copays and PBM reimbursements received — US$190,000 of December's reimbursements arrive in January, next year's income under the cash method), US$380,000 of front-store sales (sales tax collected on the taxable categories), and US$120,000 of immunizations and clinical services. Cost of goods sold: US$3.6 million — purchases of US$3.72 million, less US$88,000 of generic rebates and prompt-pay discounts, adjusted for the inventory service's December count. LIFO: adopted six years ago on Form 970 using the IPIC index method — this year's inventory inflation (brand prices up about 5 percent) produces a US$34,000 larger cost of goods sold than FIFO would, and the LIFO reserve stands at US$186,000 (the deferred inflation — the financial statements the bank receives are on LIFO under the conformity rule, with the reserve disclosed). PBM adjustments: US$96,000 of commercial post-adjudication fees withheld from remittances during the year and US$14,000 of audit recoupments (two claims with signature documentation gaps) — each a reduction of income when withheld, reconciled by the pharmacy's remittance software to the claims. Compliance: two pharmacist licenses and four technician registrations, the board permit, the DEA registration and the biennial controlled-substance inventory, the monitoring program's daily reporting, the product tracing records, HIPAA, and six PBM network credentialings. A new automated counting machine and an adherence packaging machine (US$92,000 — section 179). Net profit lands in the low-to-mid six figures — an S corporation with the owner-pharmacist's salary at the pharmacist market wage plus management, the QBI deduction phased out above the range (pharmacy is health). A neighboring pharmacy on FIFO with an estimated inventory, whose clawbacks were recorded only when the PBM sent its annual reconciliation, reported profit in the year it earned the reimbursement and a loss in the year the fees arrived — neither year right.

Official sources

Publication 538 states: “Each method produces different income results, depending on the trend of price levels at the time. In times of inflation, when prices are rising, LIFO will produce a larger cost of goods sold and a lower closing inventory.” — Internal Revenue Service, Publication 538, Accounting Periods and Methods, https://www.irs.gov/publications/p538

The DEA states: “Regardless of whether a registration is reinstated within the calendar month after expiration, federal law prohibits the handling of controlled substances or List 1 chemicals for any period of time under an expired registration.” — U.S. Drug Enforcement Administration, Registration, https://www.deadiversion.usdoj.gov/drugreg/registration.html

Practitioner note

An independent pharmacy's return turns on three numbers the pharmacy doesn't fully control: the cost of drugs whose prices rise every year, the PBM reimbursement set by contract, and the fees the PBM takes back months later. Our pharmacy files count the shelf with an inventory service in December, examine LIFO for every pharmacy whose inventory inflates (the tax on that inflation is deferrable, and the reserve is a deferred tax the buyer will price), and reconcile every PBM remittance to the claims so clawbacks land in the year they're withheld — because a pharmacy that waits for the annual reconciliation reports neither year correctly.

See also: For related guidance, see independent pharmacy entity and succession: the owner-pharmacist, the LIFO reserve, and the buyer who wants the prescription files; and browse every small business tax guide, by situation.

Next step

Fairlight Accounting is a cross-border accounting and tax practice with a U.S. Tax Desk and a Canadian Tax Desk. Our U.S. Tax Desk handles independent pharmacy returns — inventory counts and wholesaler rebate accounting, LIFO adoption and dollar-value index methods, PBM reimbursement and DIR fee reconciliation, audit recoupment treatment, front-store and over-the-counter sales tax, DEA and board of pharmacy compliance, and automation equipment elections. See pricing or book a call.